Infrastructure for Regenerative Medicine.
Graftworks serves as the tissue harvesting and processing infrastructure layer for regenerative medicine — unlocking scalable autograft and allograft tissue products from umbilical cord tissue that was previously wasted.
To accelerate the next generation of tissue harvesting and processing.
We envision a future where no umbilical cord tissue goes to waste. By replacing manual, inconsistent harvesting with automated precision, Graftworks will enable the regenerative medicine industry to scale — delivering uniform, clinically usable grafts to every patient who needs them.
To provide the automated infrastructure that transforms how cord tissue is harvested, processed, and delivered — enabling cord blood banks, tissue manufacturers, and healthcare suppliers to unlock the full potential of regenerative biologics.
The vast majority of umbilical cord tissue is discarded or stored as unusable material. We help solve this situation across the industry regardless of the reasons for processing/harvesting tissue.
Current harvesting is manual and labor-intensive. We reduce processing time to a fraction of the current manual process.
"Artisan" techniques lead to inconsistent yields and high rejection rates.
The UT Partnership
Graftworks holds exclusive rights from McGovern Medical School at University of Texas-Houston for patented tissue processing automation. This partnership is the foundation of our entire platform — bridging academic innovation in regenerative medicine with commercial-scale manufacturing.
- Three issued U.S. patents covering devices and methods.
- Exclusive rights to patented harvesting automation.
Learn More About Our Platform
See how Graftworks is transforming tissue processing for cord blood banks, tissue manufacturers, and healthcare suppliers.
Contact Us